Lee Nancy, Harris Jonathan, Garden Adam S, Straube William, Glisson Bonnie, Xia Ping, Bosch Walter, Morrison William H, Quivey Jeanne, Thorstad Wade, Jones Christopher, Ang K Kian
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10021, USA.
J Clin Oncol. 2009 Aug 1;27(22):3684-90. doi: 10.1200/JCO.2008.19.9109. Epub 2009 Jun 29.
To investigate the feasibility of intensity-modulated radiation therapy (IMRT) with or without chemotherapy, and to assess toxicities, failure patterns, and survivals in patients with nasopharyngeal carcinoma (NPC).
Radiation consisted of 70 Gy given to the planning target volumes of primary tumor plus any N+ disease and 59.4 Gy given to subclinical disease, delivered over 33 treatment days. Patients with stage T2b or greater or with N+ disease also received concurrent cisplatin (100 mg/m(2)) on days 1, 22, and 43 followed by adjuvant cisplatin (80 mg/m(2)) on day 1; fluorouracil (1,000 mg/m(2)/d) on days 1 through 4 administered every 4 weeks for three cycles. Tumor, clinical status, and acute/late toxicities were assessed. The primary objective was to test the transportability of IMRT to a multi-institutional setting.
Between February 2003 and November 2005, 68 patients with stages I through IVB NPC (of which 93.8% were WHO types 2 and 3) were enrolled. Prescribed IMRT (target delineation) was given to 83.8%, whereas 64.9% received chemotherapy per protocol. The estimated 2-year local progression-free (PF), regional PF, locoregional PF, and distant metastasis-free rates were 92.6%, 90.8%, 89.3%, and 84.7%, respectively. The estimated 2-year PF and overall survivals were 72.7% and 80.2%, respectively. Acute grade 4 mucositis occurred in 4.4%, and the worst late grade 3 toxicities were as follows: esophagus, 4.7%; mucous membranes, 3.1%; and xerostomia, 3.1%. The rate of grade 2 xerostomia at 1 year from start of IMRT was 13.5%. Only two patients complained of grade 3 xerostomia, and none had grade 4 xerostomia.
It was feasible to transport IMRT with or without chemotherapy in the treatment of NPC to a multi-institutional setting with 90% LRPF rate reproducing excellent reports from single institutions. Minimal grade 3 and lack of grade 4 xerostomia were encouraging.
探讨调强放射治疗(IMRT)联合或不联合化疗治疗鼻咽癌(NPC)的可行性,并评估其毒性、失败模式及患者生存率。
放疗方案为对原发肿瘤及任何N+病变的计划靶区给予70 Gy照射,对亚临床病灶给予59.4 Gy照射,分33天完成。T2b期及以上或N+病变的患者在第1、22和43天还接受同步顺铂(100 mg/m²)治疗,随后在第1天接受辅助顺铂(80 mg/m²)治疗;氟尿嘧啶(1000 mg/m²/d)在第1至4天给药,每4周重复一次,共三个周期。评估肿瘤情况、临床状态及急性/晚期毒性。主要目的是测试IMRT在多机构环境中的可移植性。
2003年2月至2005年11月,纳入68例I至IVB期的NPC患者(其中93.8%为WHO 2型和3型)。83.8%的患者接受了规定的IMRT(靶区勾画),而按照方案64.9%的患者接受了化疗。估计2年局部无进展(PF)、区域PF、局部区域PF和远处转移率分别为92.6%、90.8%、89.3%和84.7%。估计2年PF率和总生存率分别为72.7%和80.2%。4.4%的患者发生急性4级口腔黏膜炎,最严重的晚期3级毒性如下:食管4.7%;黏膜3.1%;口干3.1%。IMRT开始后1年2级口干发生率为13.5%。仅2例患者主诉3级口干,无4级口干患者。
在多机构环境中,IMRT联合或不联合化疗治疗NPC是可行的,局部区域无进展生存率达90%,重现了单机构的出色报告。3级毒性轻微且无4级口干令人鼓舞。